Go to Qiita Advent Calendar 2024 Top
LoginSignup
0
1

Delete article

Deleted articles cannot be recovered.

Draft of this article would be also deleted.

Are you sure you want to delete this article?

新規開発や新技術の検証、導入にまつわる記事を投稿しよう！
@kaizen_nagoya(Dr. Kiyoshi Ogawa)

メラノーマガイドラインパブリックコメントにIT関係者からの意見を出す準備 色(33)

Last updated at Posted at 2019-05-08

医療系の現状と課題
https://qiita.com/kaizen_nagoya/items/5734255c49b6eca4565d

で引用している

メラノーマガイドラインパブリックコメントの募集について
http://www.skincancer.jp/info_melanoma190415.html

について、IT関係者からの意見をどのようにまとめるかの事例を記録する。

医療システムは、主に次の３つを想定している。

計算機を内蔵している機器
解析に計算機を利用している
記録・管理に計算機を利用している

これらのソフトウェアは、従来は全く異なるOSで管理し、全く異なる通信網(network)に接続されてきた。

最近では内蔵機器のOSがLinuxだった、通信にWi-Fi, bluetoothを使っていたり、ほぼ継ぎ目なく(seamless)につなぐくとができる場合がある。

そこで、医療技術だけでなく、OS、通信、データ解析技術を統合的に設計、運用することになる。

メラノーマガイドライン序文（PDFファイル 2.30 MB）
http://www.skincancer.jp/info_melanoma_j190415.pdf
からの引用はページ数のみ

CQ統合版（PDFファイル 478 KB）
http://www.skincancer.jp/info_melanoma190415.pdf
からの引用はページ数の前にCQをつける。

確認事項

ここまでの作業で確認できたこと

  1. 用語
    専門用語以外はカタカナ語を少なくし、専門性のない概念の文字数を減らし、専門性のある内容に注力できるようにするとよい

専門用語は用語集として略号、資料URLなどをつける。
英語、日本語の対比もあるとよい。

日本語と英語の違いでの見落としの確率が減る。

  1. 参考文献
    参考文献のうち、本文がWEBにあるものはURLを必ずつける。抄録しかない場合でも、URLをつける。
    最適なURLであるかどうかは、未確認であると断る。

用語

医療専門用語がカタカナ語である場合には、専門的な考察が必要であるため意見は留保する。
しかし、医療専門用語以外のカタカナ語を多用すると、医療専門用語との区分があいまいになり、
用語定義しないで利用していると医療専門用語として使っているのかどうかが不明確になる。

CQ

p.6

その是非について十分なコンセンサスが確立していると考えられる事項（background question）については，本ガイドラインの前半部分 に新たに総論を設けてそのなかで紹介することとした．Background Question とするには議論の余地が残る重要臨床事項について，これまでと同様に臨床質問を作成し（foreground question），クリニカルクエスチョン（clinical question: CQ）として後半に記述した．

CQは、頻出単語でここでfull spellも、意味の説明もあり、略号として使うのにふさわしい。

background question, foreground questionも、BQ, FQとして用いるとよいかどうかは全文での頻度による。

言い換え案

日本語案が空欄の用語は、よい言葉がおもいあたっていないもの。
思い当たる言葉がありましたら、コメント欄などでご教示ください。
またより適切な日本語案についても同様です。

カタカナ語 日本語案 英語
ガイドライン 指針 guideline
スクリーニング 予備選別 screening
チーム 班 team
グループ 班 group
パネリスト panelist
システマティク 体系的 systematic
レビュー 見直し review
エビデンス 証拠 evidence
マニュアル 手引き manual
コンセンサス 合意 consensus
ハンドリサーチ 人手検索 hand search
テンプレート 雛形 template
アウトカム 成果 outcome
デザイン 設計 design
バイアス 偏向 bias
リスク 危険性 risk
メタアナリシス meta analysis
センター 本部, 施設 center
レポート 報告 report
バランス 均衡 balance
コスト 費用 cost
シート 表 sheet
チーフ 主任、筆頭 cheaf
メール 郵便 mail
パブリックコメント 意見公募 public comment
ロードマップ 計画図 road map
フォーマット 書式 format
テーマ 主題 thema
コメント 意見 comment
モニタリング 監視 monitoring
アンケート 質問票 questionnaire
ホームページ home page
ガイダンス 指導 guidance
チェックポイント 検査点 check point
カテゴリー 分類 category
サブグループ 分班 sub group
ストレス 圧迫 stress
ルール 規則 rule

meta analysis

Primary, secondary and meta-analysis of research. Educational Researcher 10: 3-8.
, Gene V Glass, 1976
http://www.jameslindlibrary.org/glass-gv-1976/

専門用語資料

カタカナ語 日本語 英語 略号 URL
メラノーマ
ダーモスコピー
センチネルリンパ
クリニカルクエスチョン clinical question CQ
backgroud question
foregroud question
Patients, problem population, Interventions, Comparions, controles, comparators, Outcomes PICO
Conchrance Library
PubMed
- 医学中央雑誌
- 経済的利益相反 Conflict of Interest COI
疫学
メラノサイト
腫瘍
臨床症状
病理所見
表在拡大型
末端黒子型
悪性黒子型
結節型
皮膚
粘膜
眼球脈絡膜
脳軟膜
遺伝子変異
紫外線暴露量
色素性病変
罹患率
WHO
GLOBOCAN
リンパ
BRAF
MAPキナーゼ
P13キナーゼ
NRAS
解剖学的部位
日光暴露累積量 cumulative sun damage CSD
四肢末端部 acral
粘膜部 mucosal
眼球内 uveal
malignant Spitz tumor
先天性色素性母斑
青色母斑
水平方向進展 radial growth phase
垂直方向進展 vertical growth phase
VRAF V600E
KIT
チロシンキナーゼ
膜受容体型
阻害薬
cyclin dependent kinase 4/cylinD1 CDK4/CCND1
GNAQ/GNA11
mammalian target of rapamycin) mTOR
cyclin-dependant kinase inhibitor 2A CDKN2A
PTEN
telomerase reverse transcriptase)， TERT
neurofibromin-1 NF-1
American Joint Committee on Cancer AJCC
Union for International Cancer Control UICC
臨床分類 cTNM
生検
原発巣
部分生検
全切除生検
センチネルリンパ節生検
病理学的分類 pTNM
in-transig
乳酸脱水酵素 LDH
腫瘍厚さ tumor thickness： TT
ocular micrometer
原発腫瘍評価不可能 pTX
フィブリン沈着
メラノーマin situ ．Tis
Asymmetry，Border irregularity，Color variegation，Diameter>6mm，Evolution ABCDE

#手順

p.9

ii. 投票を行う CQ に関連して，規定を超える経済的利益相反（COI）または学術的 COI，その他のCOIを有する委員は，議論に参加可能だが投票を棄権する．

経済的利益相反は投票を棄権するのは合理的。
学術的、その他が棄権する根拠は、「規定による」。

学術的COIがないような専門家はいないはずである。単に専門家を排除する印象がある。

p.13

1）利益相反の申告
2017年3月に日本医学会より公表された「診療ガイドライン策定参加資格基準ガイダンス」（以下，参加基準ガイダンス）5)に従い，ガイドライン改訂委員会委員，外部評価委員が就任時に前年にさかのぼって過去3年間分とガイドライン公表までの1年ごとの利益相反（conflict of interest: COI）の開示を行った．申告に際しては，1）委員本人のCOI，委員の配偶者，2）1親等親族または収入・財産的利益を共有する者のCOI，3）委員が所属する組織・部門にかかる組織COIを，参加基準ガイダンスの定めるCOI自己申告書にて金額区分（図1A, 1B） とともに申告した．

診療ガイドライン策定参加資格基準 ガイダンス - 日本医学会
https://www.google.co.jp/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=2ahUKEwiy7MSU64riAhXMPXAKHeUEDHEQFjAAegQIAxAC&url=http%3A%2F%2Fjams.med.or.jp%2Fguideline%2Fclinical_guidance.pdf&usg=AOvVaw08ro92lHZrZgh861u6jF5U

規定の妥当性を別途確認中。

遺伝子

遺伝子に関する資料は、従来の疫学、病理学などと連続している。
情報源および情報量の多寡の記載があるとよい。
また遺伝子に関する資料は急増しており、従来の医学論文の分析の方法によらない方法も模索するとよい。
また、経済的CIO、学術的CIOを検討するには、学術的なフィルタによらない情報源の収集が大事である。

BRAF

肺癌患者における BRAF 遺伝子変異検査の手引き
https://www.haigan.gr.jp/uploads/files/photos/1620.pdf

メラノーマにおけるBRAF V600変異の検出 宇 原 久
0238 モダンメディア 61 巻 8 号 2015[臨床検査アップデート]
http://www.eiken.co.jp/modern_media/backnumber/pdf/MM1508_04.pdf

アレイ バイオファーマ社、BRAF 遺伝子変異陽性の転移性大腸がんを対象とした BRAFTOVI®、MEKTOVI®および ERBITUX®の併用療法の第III相 BEACON CRC 試験の 安全性導入期(Safety Lead-in)結果において全生存期間の中央値 15.3 カ月を発表
https://www.ono.co.jp/jpnw/PDF/n19_0115_2.pdf

京都がん研究会メールマガジン第 166 号 (2018 年2月)
BRAF 変異陽性肺癌の最近の話題
(文責 京都大学医学部附属病院 呼吸器内科 阪森優一)
http://ganpro.med.kyoto-u.ac.jp/wp-content/uploads/2018/02/mm166_201802.pdf

BRAF遺伝子検査 ※詳細は次ページをご覧ください。 (オンコマインTM Dx TargetTest CDx システム)5,000点

平成 27 年度 学内グラント終了時報告書 日本人悪性黒色腫における体細胞遺伝子変異ならびに
バイオマーカー候補と臨床料理学的因子との関連に関する研究 寺本由紀子(国際医療センター 皮膚腫瘍科)埼玉医科大学雑誌 第 43 巻 第 1 号 平成 28 年 8 月
http://www.saitama-med.ac.jp/jsms/vol43/01/jsms43_043_047.pdf

保険適用、料金の変化

臨床検査の保険適用について(平成30年8月収載予定) BRAF 遺伝子検査
https://www.mhlw.go.jp/content/12404000/000334420.pdf

検査実施料新設のお知らせ　No.2018-58 平成 30 年 12 月　株式会社エスアールエル
https://www.srl-group.co.jp/assets/pdf/news/testing/2018-58.pdf

BRAF遺伝子検査 (オンコマインTM Dx TargetTest CDx システム) 5,000点

新規受託開始のお知らせ　項目コード:2663 No.2018-19 RAS-BRAF遺伝子変異解析 受託開始日:2018年9月8日(土)受付分より
http://www.sms.co.jp/reference/info/2018_19.pdf?PHPSESSID=581ff6a343dd7fdba8f0c20ca88fe40c

4,000点(包括点数)※4※5 (悪性腫瘍組織検査 「1」悪性腫瘍遺伝子検査) (保険請求上は、「RAS遺伝子検査」および「BRAF遺伝子検査」の2項目扱いとなります。

調査資料

直接資料に掲載されているかどうかは未確認であるが、調査の途中で有用と推定した資料の記録。
参考文献に掲載のある事項は順次連携もしくは移動予定

この皮膚悪性腫瘍診療ガイドラインについて
https://www.dermatol.or.jp/medical/guideline/skincancer/about.html

参照資料

参考文献と二次資料

Evidence-based Dermatology. Williams W, et al (eds), BMJ Books, London, 2003
The Cochrane Library：http://www.thecochranelibrary.org
BMJ Clinical Evidence：http://www.clinicalevidence.org
UpToDate：http://www.uptodate.com
欧米の主要ガイドライン

The National Comprehensive Cancer Network（NCCN）：http://www.nccn.org
National Cancer Institute Physician Data Query：http://www.cancer.gov/cancer_information/pdq/
オーストラリア政府のガイドライン：http://www.nhmrc.gov.au/publications/subjects/cancer.htm
Scottish Intercollegiate Guidelines Network （SIGN）：http://www.sign.ac.uk/

文献

GLOBOCAN: Cancer Incidence. Mortality and Prevalence Worldwide, World Health Organization, Lyon, 2001

2004年に改定あり。ResearchgateでRequest now.

参考文献

先頭100文献中URLの記載は４

  1. 斎田俊明, 真鍋求, 竹之内辰也, et al: 皮膚悪性腫瘍診療ガイドライン. 日本皮膚科学会雑誌 2007; 117: 1855-1925.
    https://minds.jcqhc.or.jp/n/med/4/med0054/G0000153/0001

  2. 土田哲也，他: 日本皮膚科学会ガイドライン 皮膚悪性腫瘍ガイドライン. 日本皮膚科学会雑誌 2015; 125: 5-75.
    https://www.dermatol.or.jp/uploads/uploads/files/guideline/guideline_SknCncr.pdf

  3. Gershenwald JE, Scolyer RA, Hess KR, et al: Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472-492.
    https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21409

  4. 小島原典子, 中山健夫, 森實敏夫, 山口直人, 吉田雅博: Minds 診療ガイドライン作成マニュアル2017. https://minds.jcqhc.or.jp/docs/minds/guideline/pdf/manual_all_2017.pdf.

  5. Ang KK, Peters LJ, Weber RS, et al: Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30: 795-798.
    https://www.ncbi.nlm.nih.gov/pubmed/7960981

  6. International Agency for Research on Cancer CI5plus Cancer Incidence in Five Continents Time Trends http://ci5.iarc.fr/CI5plus/Default.aspx.

  7. 藤澤康弘, 藤本 学: 悪性黒色腫全国統計調査：2005-2013年度の集計結果. 日皮会誌 2014; 29: 189-194.
    https://www.jstage.jst.go.jp/article/skincancer/29/2/29_189/_article/-char/ja/

  8. Surveillance Epidemiology and End Results Program (SEER) http://seer.cancer.gov.

  9. 藤澤康弘, 大塚藤男: 皮膚悪性腫瘍-基礎と臨床の最新研究動向 悪性黒色腫 皮膚悪性腫瘍の疫学調査-日本と外国の国際比較-. 日本臨牀 2013; 71: 7-12.
    https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201302234687758140&rel=0

  10. Gray-Schopfer V, Wellbrock C, Marais R: Melanoma biology and new targeted therapy. Nature 2007; 445: 851-857.

  11. 矢島伊知朗: 皮膚悪性腫瘍-基礎と臨床の最新研究動向 悪性黒色腫 悪性黒色腫の分子生物学 悪性黒色腫も発癌機序（紫外線などの環境因子との関係）. 日本臨牀 2014; 71: 107-111.

  12. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.

  13. Bastian BC: The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014; 9: 239-271.

  14. 芦田敦子: メラノーマの遺伝子異常. 日皮会誌 2018; 128: 1301-1208.

  15. Elder DE, Massi D, Scolyer R, Willemze R: WHO Classification of Skin Tumours. 4th Ed, Geneva, Switzerland, WHO Press 2018: 66-152.

  16. Ashida A, Uhara H, Kiniwa Y, et al: Assessment of BRAF and KIT mutations in Japanese melanoma patients. J Dermatol Sci 2012; 66: 240-242.

  17. 芦田敦子: 皮膚悪性腫瘍-基礎と臨床の最新研究動向- 悪性黒色腫 悪性黒色腫の分子生物学 分子生物学 チロシンキナーゼ KIT. 日本臨牀 2013; 71: 134-138.

  18. Brierley JD, Gospodarowicz JD, Wittekind C, UICC日本委員会TNM委員会: TNM悪性腫瘍の分類 第8版 日本語版, 金原出版, 東京. 2017: 184.

  19. 藤澤康弘: 悪性黒色腫調査結果（2017年報告）. 第34回日本皮膚悪性腫瘍学会学術大会プログラム・抄録集 2018: 184.

  20. Ivry GB, Ogle CA, Shim EK: Role of sun exposure in melanoma. Dermatol Surg 2006; 32: 481-492.

  21. Minagawa A, Omodaka T, Okuyama R: Melanomas and Mechanical Stress Points on the Plantar Surface of the Foot. N Engl J Med 2016; 374: 2404-2406.

  22. Kubica AW, Brewer JD: Melanoma in immunosuppressed patients. Mayo Clin Proc 2012; 87: 991-1003.

  23. 大西誉光: 皮膚悪性腫瘍-基礎と臨床の最新研究動向- 悪性黒色腫 悪性黒色腫の危険因子 宿主因子. 日本臨牀 2013; 71: 81-84.

  24. Rhodes AR, Melski JW: Small congenital nevocellular nevi and the risk of cutaneous melanoma. J Pediatr 1982; 100: 219-224.

  25. Illig L, Weidner F, Hundeiker M, et al: Congenital nevi less than or equal to 10 cm as precursors to melanoma. 52 cases, a review, and a new conception. Arch Dermatol 1985; 121: 1274-1281.

  26. McCarthy JT: ABCDs of Melanoma. Cutis 1995; 56: 313.

  27. Dinnes J, Deeks JJ, Chuchu N, et al: Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev 2018; 12: Cd011901.

  28. Gachon J, Beaulieu P, Sei JF, et al: First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005; 141: 434-438.

  29. Dinnes J, Deeks JJ, Chuchu N, et al: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. Cochrane Database Syst Rev 2018; 12: Cd011902.

  30. Carrera C, Marchetti MA, Dusza SW, et al: Validity and Reliability of Dermoscopic Criteria Used to Differentiate Nevi From Melanoma: A Web-Based International Dermoscopy Society Study. JAMA Dermatol 2016; 152: 798-806.

  31. Bichakjian CK, Halpern AC, Johnson TM, et al: Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011; 65: 1032-1047.

  32. Hieken TJ, Hernandez-Irizarry R, Boll JM, Jones Coleman JE: Accuracy of diagnostic biopsy for cutaneous melanoma: implications for surgical oncologists. Int J Surg Oncol 2013; 2013: 196493.

  33. Scolyer RA, Judge MJ, Evans A, et al: Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol 2013; 37: 1797-1814.

  34. Swetter SM, Tsao H, Bichakjian CK, et al: Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019; 80: 208-250.

  35. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesⓇ) Melanoma Version 2.2019-March 12, 2019 https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. In. 2019.

  36. Ng JC, Swain S, Dowling JP, Wolfe R, Simpson P, Kelly JW: The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol 2010; 146: 234-239.

  37. Karimipour DJ, Schwartz JL, Wang TS, et al: Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol 2005; 52: 798-802.

  38. Mills JK, White I, Diggs B, Fortino J, Vetto JT: Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma. Am J Surg 2013; 205: 585-590; discussion 590.

  39. Martin RC, 2nd, Scoggins CR, Ross MI, et al: Is incisional biopsy of melanoma harmful? Am J Surg 2005; 190: 913-917.

  40. Bong JL, Herd RM, Hunter JA: Incisional biopsy and melanoma prognosis. J Am Acad Dermatol 2002; 46: 690-694.

  41. Lowe M, Hill N, Page A, Chen S, Delman KA: The impact of shave biopsy on the management of patients with thin melanomas. Am Surg 2011; 77: 1050-1053.

  42. Molenkamp BG, Sluijter BJ, Oosterhof B, Meijer S, van Leeuwen PA: Non-radical diagnostic biopsies do not negatively influence melanoma patient survival. Ann Surg Oncol 2007; 14: 1424-1430.

  43. Zager JS, Hochwald SN, Marzban SS, et al: Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. J Am Coll Surg 2011; 212: 454-460; discussion 460-452.

  44. Ferrara G, Argenyi Z, Argenziano G, et al: The influence of clinical information in the histopathologic diagnosis of melanocytic skin neoplasms. PLoS One 2009; 4: e5375.

  45. Wang TS, Johnson TM, Cascade PN, Redman BG, Sondak VK, Schwartz JL: Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004; 51: 399-405.

  46. Hafner J, Schmid MH, Kempf W, et al: Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004; 150: 677-686.

  47. Vermeeren L, van der Ent FW, Hulsewe KW: Is there an indication for routine chest X-ray in initial staging of melanoma? J Surg Res 2011; 166: 114-119.

  48. Yancovitz M, Finelt N, Warycha MA, et al: Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007; 110: 1107-1114.

  49. Pandalai PK, Dominguez FJ, Michaelson J, Tanabe KK: Clinical value of radiographic staging in patients diagnosed with AJCC stage III melanoma. Ann Surg Oncol 2011; 18: 506-513.

  50. Morton RL, Craig JC, Thompson JF: The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol 2009; 16: 571-577.

  51. Roberts DL, Anstey AV, Barlow RJ, et al: U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002; 146: 7-17.

  52. Rueth NM, Xing Y, Chiang YJ, et al: Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg 2014; 259: 1215-1222.

  53. Haddad D, Garvey EM, Mihalik L, Pockaj BA, Gray RJ, Wasif N: Preoperative imaging for early-stage cutaneous melanoma: predictors, usage, and utility at a single institution. Am J Surg 2013; 206: 979-985; discussion 985-976.

  54. Barsky M, Cherkassky L, Vezeridis M, Miner TJ: The role of preoperative positron emission tomography/computed tomography (PET/CT) in patients with high-risk melanoma. J Surg Oncol 2014; 109: 726-729.

  55. Pflugfelder A, Kochs C, Blum A, et al: Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges 2013; 11 Suppl 6: 1-116, 111-126.

  56. Xing Y, Bronstein Y, Ross MI, et al: Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011; 103: 129-142.

  57. Aloia TA, Gershenwald JE, Andtbacka RH, et al: Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 2006; 24: 2858-2865.

  58. Bastiaannet E, Uyl-de Groot CA, Brouwers AH, et al: Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Ann Surg 2012; 255: 771-776.

  59. Davis PC, Hudgins PA, Peterman SB, Hoffman JC, Jr.: Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991; 12: 293-300.

  60. Machet L, Belot V, Naouri M, et al: Preoperative measurement of thickness of cutaneous melanoma using high-resolution 20 MHz ultrasound imaging: A monocenter prospective study and systematic review of the literature. Ultrasound Med Biol 2009; 35: 1411-1420.

  61. Chaput L, Laurent E, Pare A, et al: One-step surgical removal of cutaneous melanoma with surgical margins based on preoperative ultrasound measurement of the thickness of the melanoma. Eur J Dermatol 2018; 28: 202-208.

  62. Faries MB, Thompson JF, Cochran AJ, et al: Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017; 376: 2211-2222.

  63. Morton DL, Thompson JF, Cochran AJ, et al: Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370: 599-609.

  64. Leiter U, Stadler R, Mauch C, et al: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 2016; 17: 757-767.

  65. Chesney J, Puzanov I, Collichio F, et al: Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 2018; 36: 1658-1667.

  66. Tan JK, Ho VC: Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993; 19: 985-990.

  67. Johnston SR, Constenla DO, Moore J, et al: Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77: 1280-1286.

  68. Kroon HM, Huismans AM, Kam PC, Thompson JF: Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. J Surg Oncol 2014; 109: 348-351.

  69. Robert C, Karaszewska B, Schachter J, et al: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39.

  70. Larkin J, Hodi FS, Wolchok JD: Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 1270-1271.

  71. Wang Q, Gao J, Wu X: Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol 2018; 58: 125-135.

  72. Schadendorf D, Long GV, Stroiakovski D, et al: Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 2017; 82: 45-55.

  73. Long GV, Flaherty KT, Stroyakovskiy D, et al: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017; 28: 1631-1639.

  74. Drilon A, Laetsch TW, Kummar S, et al: Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-739.

  75. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R: Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol 2018; 2018

  76. Swetter SM, Tsao H, Bichakjian CK, et al: Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019; 80: 208-250.

  77. Garbe C, Peris K, Hauschild A, et al: Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer 2016; 63: 201-217.

  78. Hayward NK, Wilmott JS, Waddell N, et al: Whole-genome landscapes of major melanoma subtypes. Nature 2017; 545: 175-180.

  79. Hayward NK, Wilmott JS, Waddell N, et al: Whole-genome landscapes of major melanoma subtypes. Nature 2017; 545: 175-180.

  80. Fujisawa Y, Yoshino K, Otsuka A, et al: Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. J Dermatol Sci 2018; 89: 60-66.

  81. Eedy DJ: Surgical treatment of melanoma. Br J Dermatol 2003; 149: 2-12.

  82. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998; 351: 793-796.

  83. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al: Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89: 1495-1501.

  84. Balch CM, Soong SJ, Smith T, et al: Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8: 101-108.

  85. Khayat D, Rixe O, Martin G, et al: Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003; 97: 1941-1946.

  86. Thomas JM, Newton-Bishop J, A'Hern R, et al: Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-766.

  87. Gillgren P, Drzewiecki KT, Niin M, et al: 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011; 378: 1635-1642.

  88. Hayes AJ, Maynard L, Coombes G, et al: Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol 2016; 17: 184-192.

  89. Kunishige JH, Brodland DG, Zitelli JA: Surgical margins for melanoma in situ. J Am Acad Dermatol 2012; 66: 438-444.

  90. Bartoli C, Bono A, Clemente C, Del Prato ID, Zurrida S, Cascinelli N: Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer 1996; 77: 888-892.

  91. Grotz TE, Glorioso JM, Pockaj BA, Harmsen WS, Jakub JW: Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery 2013; 153: 535-541.

  92. Nakamura Y, Tanaka K, Shibata T, et al: Confirmatory trial of non-amputative digit preservation surgery in subungual melanoma: JCOG1602 (J-NAIL study). J Clin Oncol 2018; 36: (suppl; abstr TPS9607).

  93. Amaria RN, Prieto PA, Tetzlaff MT, et al: Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 2018; 19: 181-193.

  94. Amaria RN, Reddy SM, Tawbi HA, et al: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018; 24: 1649-1654.

  95. Deutsch GB, Flaherty DC, Kirchoff DD, et al: Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy. JAMA Surg 2017; 152: 672-678.

  96. Harpole DH, Jr., Johnson CM, Wolfe WG, George SL, Seigler HF: Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992; 103: 743-748; discussion 748-750.

  97. Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL: Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995; 110: 119-128; discussion 129.

  98. Schuhan C, Muley T, Dienemann H, Pfannschmidt J: Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac Cardiovasc Surg 2011; 59: 158-162.

  99. Weber J, Mandala M, Del Vecchio M, et al: Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377: 1824-1835.

  100. Long GV, Grob JJ, Nathan P, et al: Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 2016; 17: 1743-1754.

  101. Schachter J, Ribas A, Long GV, et al: Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390: 1853-1862.

  102. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377: 1345-1356.

  103. Gould EA, Winship T, Philbin PH, Kerr HH: Observations on a "sentinel node" in cancer of the parotid. Cancer 1960; 13: 77-78.

  104. Cabanas RM: An approach for the treatment of penile carcinoma. Cancer 1977; 39: 456-466.

  105. Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.

  106. Morton DL, Thompson JF, Cochran AJ, et al: Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370: 599-609.

  107. 宇原 久, 山本明史, 清原祥夫, 斎田俊明: メラノーマの原発巣の厚さとセンチネルリンパ節の転移率についての検討. 日皮会誌 2008; 118: 3083-3088.

  108. Wong SL, Faries MB, Kennedy EB, et al: Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol 2018; 36: 399-413.

  109. 川村龍吉, 小川陽一, 猪爪隆史, et al: RI・色素法併用によるセンチネルリンパ節生検を施行した皮膚悪性腫瘍135例の検討. 日皮会誌 2011; 121: 2265-2271.

  110. 藤澤康弘, 中村泰大, 丸山 浩, 中村貴之, 川内康弘, 大塚藤男: インドシアニングリーンの蛍光を用いたセンチネルリンパ節生検50例のまとめ. 日皮会誌 2012; 122: 2875-2883.

  111. Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN: Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 1993; 2: 303-308.

  112. McMasters KM, Reintgen DS, Ross MI, et al: Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol 2001; 8: 192-197.

  113. Fujisawa Y, Nakamura Y, Kawachi Y, Otsuka F: Indocyanine green fluorescence-navigated sentinel node biopsy showed higher sensitivity than the radioisotope or blue dye method, which may help to reduce false-negative cases in skin cancer. J Surg Oncol 2012; 106: 41-45.

  114. Nakamura Y, Fujisawa Y, Nakamura Y, et al: Improvement of the sentinel lymph node detection rate of cervical sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green in head and neck skin cancer. The Journal of Dermatology 2013; 40: 453-457.

  115. Shichinohe R, Furukawa H, Sekido M, et al: Direction of innervation after interpositional nerve graft between facial and hypoglossal nerves in individuals with or without facial palsy: a rat model for treating incomplete facial palsy. J Plast Reconstr Aesthet Surg 2012; 65: 763-770.

  116. Namikawa K, Tsutsumida A, Tanaka R, Kato J, Yamazaki N: Limitation of indocyanine green fluorescence in identifying sentinel lymph node prior to skin incision in cutaneous melanoma. International Journal of Clinical Oncology 2014; 19: 198-203.

  117. Masud D, Bisarya K, Svensson W, Jallali N: Surgical evaluation of the use SPECT-CT in sentinel lymph node biopsies in primary cutaneous melanoma. J Plast Reconstr Aesthet Surg 2017; 70: 40-41.

  118. Lerman H, Lievshitz G, Zak O, Metser U, Schneebaum S, Even-Sapir E: Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med 2007; 48: 201-206.

  119. Lopez-Rodriguez E, Garcia-Gomez FJ, Alvarez-Perez RM, et al: Role of SPECT-CT in sentinel lymph node biopsy in patients diagnosed with head and neck melanoma. Rev Esp Med Nucl Imagen Mol 2016; 35: 22-28.

  120. 黒岡定浩, 並川健二郎, 堤田 新, 田中亮多, 加藤潤史, 山崎直也: 頭頸部皮膚悪性黒色腫に対するセンチネルリンパ節生検及び頸部リンパ節郭清術についての検討(第一報 センチネルリンパ節生検について). 日皮会誌 2013; 123: 1045-1050.

  121. 千々和秀記, 進武一郎, 坂本菊男, 梅野博仁, 中島 格: 前頭部・顔面皮膚悪性腫瘍リンパ節転移に対する郭清範囲についての臨床的検討. 日耳鼻会報 2007; 110: 103-106.

  122. Hayashi T, Furukawa H, Oyama A, Funayama E, Saito A, Yamamoto Y: Dominant lymph drainage in the facial region: evaluation of lymph nodes of facial melanoma patients. International Journal of Clinical Oncology 2012; 17: 330-335.

  123. Ishihara T, Kageshita T, Matsushita S, Ono T: Investigation of sentinel lymph nodes of the axillary and cubital regions in upper-extremity malignant skin tumors: a series of 15 patients. Int J Clin Oncol 2003; 8: 297-300.

  124. Fujiwara M, Suzuki A, Mizukami T, Nagata T, Ito T, Fukamizu H: Mid-arm lymph nodes dissection for melanoma. J Plast Reconstr Aesthet Surg 2010; 63: 1561-1564.

  125. Veenstra HJ, Klop WM, Speijers MJ, et al: Lymphatic drainage patterns from melanomas on the shoulder or upper trunk to cervical lymph nodes and implications for the extent of neck dissection. Ann Surg Oncol 2012; 19: 3906-3912.

  126. van der Ploeg IM, Kroon BB, Valdes Olmos RA, Nieweg OE: Evaluation of lymphatic drainage patterns to the groin and implications for the extent of groin dissection in melanoma patients. Ann Surg Oncol 2009; 16: 2994-2999.

  127. 中村泰大, 石塚洋典, 鬼澤沙織, 大塚藤男: 【メラノーマ】 臨床例 悪性黒色腫に対する膝窩リンパ節郭清 膝窩リンパ節の取り扱いについて. 皮膚病診療 2010; 32: 745-748.

  128. Steen ST, Kargozaran H, Moran CJ, Shin-Sim M, Morton DL, Faries MB: Management of popliteal sentinel nodes in melanoma. J Am Coll Surg 2011; 213: 180-186; discussion 186-187.

  129. Menes TS, Schachter J, Steinmetz AP, Hardoff R, Gutman H: Lymphatic drainage to the popliteal basin in distal lower extremity malignant melanoma. Arch Surg 2004; 139: 1002-1006.

  130. Faries MB, Thompson JF, Cochran AJ, et al: Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017; 376: 2211-2222.

  131. Mack LA, McKinnon JG: Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol 2004; 86: 189-199.

  132. White N, Yap LH, Srivastava S: Lymphadenectomy for melanoma in the clinically N1 neck: radical, modified radical, or selective? J Craniofac Surg 2009; 20: 385-388.

  133. O'Brien CJ, Petersen-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI: Radical, modified, and selective neck dissection for cutaneous malignant melanoma. Head Neck 1995; 17: 232-241.

  134. Pu LL, Wells KE, Cruse CW, Shons AR, Reintgen DS: Prevalence of additional positive lymph nodes in complete lymphadenectomy specimens after positive sentinel lymphadenectomy findings for early-stage melanoma of the head and neck. Plast Reconstr Surg 2003; 112: 43-49.

  135. 黒岡定浩, 並川健二郎, 堤田 新, 田中亮多, 加藤潤史, 山崎直也: 頭頸部皮膚悪性腫瘍に対するセンチネルリンパ節生検及び頸部リンパ節郭清術についての検討(第二報 頸部リンパ節郭清術について). 日皮会誌 2013; 123: 1051-1057.

  136. 中村泰大: 【皮膚悪性腫瘍-基礎と臨床の最新研究動向-】 悪性黒色腫 悪性黒色腫の治療 外科的治療 手術適応と方法論(原発巣、所属リンパ節転移). 日本臨牀 2013; 71: 299-302.

  137. 並川健二郎, 山崎直也, 山本明史, et al: 頭頸部皮膚原発悪性黒色腫の頸部郭清術. 日皮会誌 2006; 116: 1201-1206.

  138. Garbe C, Hauschild A, Volkenandt M, et al: Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res 2008; 18: 152-160.

  139. Namm JP, Chang AE, Cimmino VM, Rees RS, Johnson TM, Sabel MS: Is a level III dissection necessary for a positive sentinel lymph node in melanoma? J Surg Oncol 2012; 105: 225-228.

  140. de Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ: Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. Eur J Surg Oncol 2005; 31: 778-783.

  141. 中村泰大, 寺本由紀子, 山田勝裕, 佐藤さゆり, 山本明史: メラノーマ 外科療法 悪性黒色腫における所属リンパ節郭清の方針と手術手技 世界の趨勢と当科の現状. Skin Cancer 2014; 29: 114-116.

  142. Baas PC, Schraffordt Koops H, Hoekstra HJ, van Bruggen JJ, van der Weele LT, Oldhoff J: Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity. Arch Surg 1992; 127: 281-286.

  143. Abbas S, Seitz M: Systematic review and meta-analysis of the used surgical techniques to reduce leg lymphedema following radical inguinal nodes dissection. Surg Oncol 2011; 20: 88-96.

  144. 梅田 整, 秦維郎, 飯田秀夫, 森弘樹, 田中和行, 鈴木真澄: 鼠径リンパ節郭清術術後皮弁壊死について. Skin Cancer 2000; 15: 154-158.

  145. Furukawa H, Hayashi T, Oyama A, et al: Effectiveness of intraoperative indocyanine-green fluorescence angiography during inguinal lymph node dissection
    for skin cancer to prevent postoperative wound dehiscence. Surg Today 2015; 45: 973-978.

  146. 柴田真一, 安江 敬, 榊原章浩, 吉野 能, 吉川羊子, 富田 靖: 鼠径・骨盤内リンパ節郭清の治療を行った悪性黒色腫8例について. Skin Cancer 2005; 20: 150-153.

  147. 堤田 新, 山本有平, 古川洋志, 杉原平樹, 吉田哲憲: メラノーマの鼠径リンパ節微小転移例におけるリンパ節郭清範囲の検討 センチネルリンパ節転移陽性例の郭清はどこまですべきか? Skin Cancer 2006; 20: 264-267.

  148. KretschmerL., NeumannC., PreusserK.P., MarschW.C.: Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin--an analysis of survival and local recurrence. Acta Oncol 2001; 40: 72-78.

  149. 中村泰大, 許雪珠, 藤沢康弘, 石井良征, 高橋毅法, 大塚藤男: 下肢領域stage III悪性黒色腫における鼠径リンパ節郭清群と鼠径骨盤リンパ節郭清群との比較検討. 日皮会誌 2006; 116: 1599-1604.

  150. Egger ME, Brown RE, Roach BA, et al: Addition of an iliac/obturator lymph node dissection does not improve nodal recurrence or survival in melanoma. J Am Coll Surg 2014; 219: 101-108.

  151. Chang SB, Askew RL, Xing Y, et al: Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol 2010; 17: 2764-2772.

  152. Teixeira F, Moutinho V, Jr., Akaishi E, et al: Popliteal lymph node dissection for metastases of cutaneous malignant melanoma. World J Surg Oncol 2014; 12: 135.

  153. Karakousis CP: Therapeutic node dissections in malignant melanoma. Ann Surg Oncol 1998; 5: 473-482.

  154. Pidhorecky I, Lee RJ, Proulx G, et al: Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol 2001; 8: 109-115.

  155. Meyer T, Merkel S, Gohl J, Hohenberger W: Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. Eur J Surg Oncol 2002; 28: 424-430.

  156. Henderson MA, Burmeister BH, Ainslie J, et al: Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 2015; 16: 1049-1060.

  157. Agrawal S, Kane JM, 3rd, Guadagnolo BA, Kraybill WG, Ballo MT: The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009; 115: 5836-5844.

  158. Pinkham MB, Foote MC, Burmeister E, et al: Stage III melanoma in the axilla: patterns of regional recurrence after surgery with and without adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2013; 86: 702-708.

  159. Strom T, Torres-Roca JF, Parekh A, et al: Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. J Natl Compr Canc Netw 2017; 15: 473-482.

  160. Kim YJ, Song SY, Kim W, et al: Feasibility of Postoperative Radiotherapy Using Conventional Fractionation for Lymph Node Metastasis from Cutaneous Melanoma. Anticancer Res 2017; 37: 4239-4246.

  161. Barbour S, Mark Smithers B, Allan C, et al: Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and
    Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable? Ann Surg Oncol 2015; 22: 4052-4059.

  162. Bibault JE, Dewas S, Mirabel X, et al: Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 2011; 6: 12.

  163. Gojkovic-Horvat A, Jancar B, Blas M, et al: Adjuvant radiotherapy for palpable melanoma metastases to the groin: when to irradiate? Int J Radiat Oncol Biol Phys 2012; 83: 310-316.

  164. Hamming-Vrieze O, Balm AJ, Heemsbergen WD, Hooft van Huysduynen T, Rasch CR: Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy. Arch Otolaryngol Head Neck Surg 2009; 135: 795-800.

  165. Martin RC, Shannon KF, Quinn MJ, et al: The management of cervical lymph nodes in patients with cutaneous melanoma. Ann Surg Oncol 2012; 19: 3926-3932.

  166. Moncrieff MD, Martin R, O'Brien CJ, et al: Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients? Ann Surg Oncol 2008; 15: 3022-3027.

  167. Konefal JB, Emami B, Pilepich MV: Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 1987; 164: 607-610.

  168. Bentzen SM, Overgaard J, Thames HD, et al: Clinical radiobiology of malignant melanoma. Radiother Oncol 1989; 16: 169-182.

  169. Chang DT, Amdur RJ, Morris CG, Mendenhall WM: Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006; 66: 1051-1055.

  170. Grob JJ, Amonkar MM, Karaszewska B, et al: Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in
    patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 2015; 16: 1389-1398.

  171. Farshad A, Burg G, Panizzon R, Dummer R: A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146: 1042-1046.

  172. Tsang RW, Liu FF, Wells W, Payne DG: Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994; 130: 1008-1012.

  173. Koto M, Demizu Y, Saitoh JI, et al: Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys 2017; 97: 1054-1060.

  174. Verma V, Mehta MP: Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma. Clin Oncol (R Coll Radiol) 2016; 28: e17-27.

  175. Demizu Y, Fujii O, Terashima K, et al: Particle therapy for mucosal melanoma of the head and neck. A single-institution retrospective comparison of proton and carbon ion therapy. Strahlenther Onkol 2014; 190: 186-191.

  176. Zenda S, Akimoto T, Mizumoto M, et al: Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses. Radiother Oncol 2016; 118: 267-271.

  177. Hiratsuka J, Fukuda H. Malignant melanoma. 10: Springer Science & Business Media. 2012.

  178. Mishima Y: Melanoma and nonmelanoma neutron capture therapy using gene therapy: overview. Advances in neutron capture therapy Volume I medicine and physics 1997; 1: 10-25.

  179. Katz HR: The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int J Radiat Oncol Biol Phys 1981; 7: 907-911.

  180. Overgaard J: The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys 1986; 12: 867-872.

  181. Forschner A, Heinrich V, Pflugfelder A, Meier F, Garbe C: The role of radiotherapy in the overall treatment of melanoma. Clin Dermatol 2013; 31: 282-289.

  182. Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 10: 1037-1044.

  183. Brown PD, Ballman KV, Cerhan JH, et al: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18: 1049-1060.

  184. Yamamoto M, Serizawa T, Shuto T, et al: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 2014; 15: 387-395.

  185. Lucas JT, Jr., Colmer HGt, White L, et al: Competing Risk Analysis of Neurologic versus Nonneurologic Death in Patients Undergoing Radiosurgical Salvage After Whole-Brain Radiation Therapy Failure: Who Actually Dies of Their Brain Metastases? Int J Radiat Oncol Biol Phys 2015; 92: 1008-1015.

  186. Gonzalez-Martinez J, Hernandez L, Zamorano L, et al: Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J Neurosurg 2002; 97: 494-498.

  187. Koc M, McGregor J, Grecula J, Bauer CJ, Gupta N, Gahbauer RA: Gamma Knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors. J Neurooncol 2005; 71: 307-313.

  188. Grob JJ, Regis J, Laurans R, et al: Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur J Cancer 1998; 34: 1187-1192.

  189. Neal MT, Chan MD, Lucas JT, Jr., et al: Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg 2014; 82: 1250-1255.

  190. Liew DN, Kano H, Kondziolka D, et al: Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011; 114: 769-779.

  191. Mathieu D, Kondziolka D, Cooper PB, et al: Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 2007; 60: 471-481; discussion 481-472.

  192. Radbill AE, Fiveash JF, Falkenberg ET, et al: Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 2004; 101: 825-833.

  193. Herfarth KK, Izwekowa O, Thilmann C, et al: Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. Strahlenther Onkol 2003; 179: 366-371.

  194. Qin R, Olson A, Singh B, et al: Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. Int J Radiat Oncol Biol Phys 2016; 96: 72-77.

  195. Tazi K, Hathaway A, Chiuzan C, Shirai K: Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 2015; 4: 1-6.

  196. Schoenfeld JD, Mahadevan A, Floyd SR, et al: Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer 2015; 3: 50.

  197. Murphy JB, Morton JJ: The Effect of Roentgen Rays on the Rate of Growth of Spontaneous Tumors in Mice. J Exp Med 1915; 22: 800-803.

  198. Demaria S, Kawashima N, Yang AM, et al: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11: 728-734.

  199. Abuodeh Y, Venkat P, Kim S: Systematic review of case reports on the abscopal effect. Curr Probl Cancer 2016; 40: 25-37.

  200. Yamazaki N, Uhara H, Wada H, et al: Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma. J Dermatol 2016; 43: 1146-1153.

  201. Eggermont AM, Suciu S, Santinami M, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126.

  202. Eggermont AM, Suciu S, Testori A, et al: Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012; 30: 3810-3818.

  203. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.

  204. Kirkwood JM, Manola J, Ibrahim J, et al: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-1677.

  205. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V: Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013; 6: CD008955.

  206. Hauschild A, Gogas H, Tarhini A, et al: Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112: 982-994.

  207. Eggermont AM, Suciu S, Testori A, et al: Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48: 218-225.

  208. Maio M, Lewis K, Demidov L, et al: Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2018; 19: 510-520.

  209. Long GV, Hauschild A, Santinami M, et al: Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 377: 1813-1823.

  210. Hauschild A, Dummer R, Schadendorf D, et al: Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol 2018: JCO1801219.

  211. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522-530.

  212. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al: Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016; 375: 1845-1855.

  213. Eggermont AMM, Blank CU, Mandala M, et al: Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018; 378: 1789-1801.

  214. Yamamoto A, Ishihara K: Clinical study of DAV + IFN-β therapy (combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-β) for malignant melanoma. Int J Immunotherapy 1996; 12: 73-78.

  215. 藤澤康弘, 大塚藤男, 日本皮膚悪性腫瘍学会皮膚癌予後統計調査委員会悪性黒色腫全国追跡調査グループ: 術後補助療法(DAVFeron、フェロン療法、フェロン維持療法)は悪性黒色腫ステージII・III患者の予後を改善するか 831例の解析. 日皮会誌 2012; 122: 2305-2311.

  216. Matsumoto T, Yokota K, Sawada M, et al: Postoperative DAV-IFN-beta therapy does not improve survival rates of stage II and stage III melanoma patients significantly. J Eur Acad Dermatol Venereol 2013; 27: 1514-1520.

  217. 高田 実, 八田尚人, 竹原和彦: 悪性黒色腫の術後補助化学療法による治療関連白血病 1例の報告と補助化学療法を受けた73例の追跡調査. 日皮会誌 2000; 110: 297-300.

  218. 紺野隆之, 日下部順子, 三浦 歩, et al: 悪性黒色腫のDAVフェロン療法中に発症した骨髄異形成症候群の2例. 臨皮 2006; 60: 71-75.

  219. 石原和之: Human Fibroblast Interferon (Hu IFN-β)による皮膚悪性腫瘍に対する臨床的研究 局所投与を中心とした検討. 日癌治会誌 1983; 18: 41-53.

  220. Aoyagi S, Hata H, Homma E, Shimizu H: Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study. Oncology 2012; 82: 139-146.

  221. Yanagi T, Hata H, Homma E, Kitamura S, Imafuku K, Shimizu H: Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis. Clin Exp Dermatol 2017; 42: 781-785.

  222. Namikawa K, Tsutsumida A, Mizutani T, et al: Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON). Jpn J Clin Oncol 2017; 47: 664-667.

  223. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.

  224. Addeo R, Zappavigna S, Luce A, Facchini S, Caraglia M: Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert Opin Drug Saf 2013; 12: 729-740.

  225. Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-1125.

  226. Guida M, Tommasi S, Strippoli S, et al: The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). BMC Cancer 2018; 18: 552.

  227. Grob JJ, Amonkar MM, Martin-Algarra S, et al: Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann Oncol 2014; 25: 1428-1436.

  228. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.

  229. Sakaizawa K, Ashida A, Uchiyama A, et al: Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. J Dermatol Sci 2015; 80: 33-37.

  230. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516-523.

  231. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68: 1403-1405.

  232. Chiarion Sileni V, Nortilli R, Aversa SM, et al: Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001; 11: 189-196.

  233. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751.

  234. 宇原 久, 斎田俊明: 進行期悪性黒色腫に対するdacarbazine, nimustine, cisplatin,tamoxifen併用療法（DAC-Tam療法: cisplatin1回投与法）の治療成績. 日皮会誌 2000; 110: 979-982.

  235. Flaherty KT, Lee SJ, Zhao F, et al: Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013; 31: 373-379.

  236. Kim KB, Sosman JA, Fruehauf JP, et al: BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012; 30: 34-41.

  237. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.

  238. McArthur GA, Chapman PB, Robert C, et al: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-332.

  239. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.

  240. Long GV, Flaherty KT, Stroyakovskiy D, et al: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017; 28: 1631-1639.

  241. Schadendorf D, Long GV, Stroiakovski D, et al: Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 2017; 82: 45-55.

  242. Ascierto PA, McArthur GA, Dreno B, et al: Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016; 17: 1248-1260.

  243. Dummer R, Ascierto PA, Gogas HJ, et al: Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018; 19: 1315-1327.

  244. Yamazaki N, Tsutsumida A, Takahashi A, et al: Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma. J Dermatol 2018; 45: 397-407.

  245. Davies MA, Saiag P, Robert C, et al: Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017; 18: 863-873.

  246. Tawbi HA, Forsyth PA, Algazi A, et al: Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med 2018; 379: 722-730.

  247. Fife KM, Colman MH, Stevens GN, et al: Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22: 1293-1300.

  248. Sampson JH, Carter JH, Jr., Friedman AH, Seigler HF: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88: 11-20.

  249. Mendez IM, Del Maestro RF: Cerebral metastases from malignant melanoma. Can J Neurol Sci 1988; 15: 119-123.

  250. Namikawa K, Kiyohara Y, Takenouchi T, et al: Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. Eur J Cancer 2018; 105: 114-126.

  251. Yamazaki N, Kiyohara Y, Uhara H, et al: Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. Cancer Sci 2017; 108: 1223-1230.

  252. Yamazaki N, Takenouchi T, Fujimoto M, et al: Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol 2017; 79: 651-660.

  253. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.

  254. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.

  255. Ascierto PA, Del Vecchio M, Robert C, et al: Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017; 18: 611-622.

  256. Schadendorf D, Hodi FS, Robert C, et al: Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33: 1889-1894.

  257. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372: 2521-2532.

  258. Weber JS, Gibney G, Sullivan RJ, et al: Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016; 17: 943-955.

  259. Zimmer L, Apuri S, Eroglu Z, et al: Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer 2017; 75: 47-55.

  260. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;

  261. D'Angelo SP, Larkin J, Sosman JA, et al: Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol 2017; 35: 226-235.

  262. Long GV, Atkinson V, Lo S, et al: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018; 19: 672-681.

  263. Blank CU, Rozeman EA, Fanchi LF, et al: Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018; 24: 1655-1661.

  264. Margolin K, Ernstoff MS, Hamid O, et al: Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465.

  265. Le DT, Durham JN, Smith KN, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409-413.

  266. Sunshine J, Taube JM: PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015; 23: 32-38.

  267. Tumeh PC, Harview CL, Yearley JH, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.

  268. Robert C, Ribas A, Hamid O, et al: Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol 2018; 36: 1668-1674.

  269. Joseph RW, Elassaiss-Schaap J, Kefford R, et al: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res 2018;

  270. Prieto PA, Yang JC, Sherry RM, et al: CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-2047.

  271. Zaretsky JM, Garcia-Diaz A, Shin DS, et al: Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 2016; 375: 819-829.

  272. Sade-Feldman M, Jiao YJ, Chen JH, et al: Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun 2017; 8: 1136.

  273. Sznol M, Ferrucci PF, Hogg D, et al: Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol 2017; 35: 3815-3822.

  274. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA: Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21: 371-381.

  275. Horvat TZ, Adel NG, Dang TO, et al: Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33: 3193-3198.

  276. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS: Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 2016; 22: 886-894.

  277. Nakamura Y, Tanaka R, Asami Y, et al: Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol 2017; 44: 117-122

<この項は書きかけです。順次追記します。>
This article is not completed. I will add some words and/or centences in order.

自己記事一覧

Qiitaで逆リンクを表示しなくなったような気がする。時々、スマフォで表示するとあらわっることがあり、完全に削除したのではなさそう。

４月以降、せっせとリンクリストを作り、統計を取って確率を説明しようとしている。
2025年２月末を目標にしている。

一覧の一覧( The directory of directories of mine.) Qiita(100)
https://qiita.com/kaizen_nagoya/items/7eb0e006543886138f39

仮説（0）一覧（目標100現在40）
https://qiita.com/kaizen_nagoya/items/f000506fe1837b3590df

Qiita(0)Qiita関連記事一覧（自分）
https://qiita.com/kaizen_nagoya/items/58db5fbf036b28e9dfa6

Error一覧 error(0)
https://qiita.com/kaizen_nagoya/items/48b6cbc8d68eae2c42b8

C++ Support(0)　
https://qiita.com/kaizen_nagoya/items/8720d26f762369a80514

Coding(0) Rules, C, Secure, MISRA and so on
https://qiita.com/kaizen_nagoya/items/400725644a8a0e90fbb0

Ethernet 記事一覧　Ethernet(0)
https://qiita.com/kaizen_nagoya/items/88d35e99f74aefc98794

Wireshark 一覧 wireshark(0)、Ethernet(48)
https://qiita.com/kaizen_nagoya/items/fbed841f61875c4731d0

線網（Wi-Fi）空中線(antenna)(0) 記事一覧(118/300目標)
https://qiita.com/kaizen_nagoya/items/5e5464ac2b24bd4cd001

なぜdockerで機械学習するか 書籍・ソース一覧作成中 (目標100)
https://qiita.com/kaizen_nagoya/items/ddd12477544bf5ba85e2

プログラムちょい替え（0）一覧:4件
https://qiita.com/kaizen_nagoya/items/296d87ef4bfd516bc394

言語処理100本ノックをdockerで。python覚えるのに最適。:10+12
https://qiita.com/kaizen_nagoya/items/7e7eb7c543e0c18438c4

Python(0)記事をまとめたい。
https://qiita.com/kaizen_nagoya/items/088c57d70ab6904ebb53

安全（0）安全工学シンポジウムに向けて: 21
https://qiita.com/kaizen_nagoya/items/c5d78f3def8195cb2409

プログラマによる、プログラマのための、統計(0)と確率のプログラミングとその後
https://qiita.com/kaizen_nagoya/items/6e9897eb641268766909

転職(0)一覧
https://qiita.com/kaizen_nagoya/items/f77520d378d33451d6fe

物理記事　上位100
https://qiita.com/kaizen_nagoya/items/66e90fe31fbe3facc6ff

量子(0) 計算機, 量子力学
https://qiita.com/kaizen_nagoya/items/1cd954cb0eed92879fd4

数学関連記事１００
https://qiita.com/kaizen_nagoya/items/d8dadb49a6397e854c6d

統計(0)一覧
https://qiita.com/kaizen_nagoya/items/80d3b221807e53e88aba

図(0) state, sequence and timing. UML and お絵描き
https://qiita.com/kaizen_nagoya/items/60440a882146aeee9e8f

品質一覧
https://qiita.com/kaizen_nagoya/items/2b99b8e9db6d94b2e971

言語・文学記事　１００
https://qiita.com/kaizen_nagoya/items/42d58d5ef7fb53c407d6

医工連携関連記事一覧
https://qiita.com/kaizen_nagoya/items/6ab51c12ba51bc260a82

自動車　記事　１００
https://qiita.com/kaizen_nagoya/items/f7f0b9ab36569ad409c5

通信記事１００
https://qiita.com/kaizen_nagoya/items/1d67de5e1cd207b05ef7

日本語（０）一欄
https://qiita.com/kaizen_nagoya/items/7498dcfa3a9ba7fd1e68

英語(0) 一覧
https://qiita.com/kaizen_nagoya/items/680e3f5cbf9430486c7d

音楽　一覧(0)
https://qiita.com/kaizen_nagoya/items/b6e5f42bbfe3bbe40f5d

「@kazuo_reve 新人の方によく展開している有益な情報」確認一覧
https://qiita.com/kaizen_nagoya/items/b9380888d1e5a042646b

鉄道（０）鉄道のシステム考察はてっちゃんがてつだってくれる
https://qiita.com/kaizen_nagoya/items/faa4ea03d91d901a618a

OSEK OS設計の基礎　OSEK(100)
https://qiita.com/kaizen_nagoya/items/7528a22a14242d2d58a3

coding (101) 一覧を作成し始めた。omake:最近のQiitaで表示しない5つの事象
https://qiita.com/kaizen_nagoya/items/20667f09f19598aedb68

官公庁・学校・公的団体（NPOを含む）システムの課題、官（０）
https://qiita.com/kaizen_nagoya/items/04ee6eaf7ec13d3af4c3

「はじめての」シリーズ　 ベクタージャパン　
https://qiita.com/kaizen_nagoya/items/2e41634f6e21a3cf74eb

AUTOSAR(0)Qiita記事一覧, OSEK(75)
https://qiita.com/kaizen_nagoya/items/89c07961b59a8754c869

プログラマが知っていると良い「公序良俗」
https://qiita.com/kaizen_nagoya/items/9fe7c0dfac2fbd77a945

LaTeX(0) 一覧　
https://qiita.com/kaizen_nagoya/items/e3f7dafacab58c499792

自動制御、制御工学一覧（０）
https://qiita.com/kaizen_nagoya/items/7767a4e19a6ae1479e6b

Rust(0) 一覧　
https://qiita.com/kaizen_nagoya/items/5e8bb080ba6ca0281927

関連資料

' @kazuo_reve 私が効果を確認した「小川メソッド」
https://qiita.com/kazuo_reve/items/a3ea1d9171deeccc04da

' @kazuo_reve 新人の方によく展開している有益な情報
https://qiita.com/kazuo_reve/items/d1a3f0ee48e24bba38f1

' @kazuo_reve Vモデルについて勘違いしていたと思ったこと
https://qiita.com/kazuo_reve/items/46fddb094563bd9b2e1e

Engineering Festa 2024前に必読記事一覧

programの本質は計画だ。programは設計だ。
https://qiita.com/kaizen_nagoya/items/c8545a769c246a458c27

登壇直後版 色使い(JIS安全色) Qiita Engineer Festa 2023〜私しか得しないニッチな技術でLT〜 スライド編 0.15
https://qiita.com/kaizen_nagoya/items/f0d3070d839f4f735b2b

プログラマが知っていると良い「公序良俗」
https://qiita.com/kaizen_nagoya/items/9fe7c0dfac2fbd77a945

逆も真：社会人が最初に確かめるとよいこと。OSEK(69)、Ethernet(59)
https://qiita.com/kaizen_nagoya/items/39afe4a728a31b903ddc

統計の嘘。仮説（127）
https://qiita.com/kaizen_nagoya/items/63b48ecf258a3471c51b

自分の言葉だけで論理展開できるのが天才なら、文章の引用だけで論理展開できるのが秀才だ。仮説（136）
https://qiita.com/kaizen_nagoya/items/97cf07b9e24f860624dd

参考文献駆動執筆(references driven writing)・デンソークリエイト編
https://qiita.com/kaizen_nagoya/items/b27b3f58b8bf265a5cd1

「何を」よりも「誰を」。１０年後のために今見習いたい人たち
https://qiita.com/kaizen_nagoya/items/8045978b16eb49d572b2

Qiitaの記事に３段階または５段階で到達するための方法
https://qiita.com/kaizen_nagoya/items/6e9298296852325adc5e

出力(output)と呼ばないで。これは状態(state)です。
https://qiita.com/kaizen_nagoya/items/80b8b5913b2748867840

coding (101) 一覧を作成し始めた。omake:最近のQiitaで表示しない5つの事象
https://qiita.com/kaizen_nagoya/items/20667f09f19598aedb68

あなたは「勘違いまとめ」から、勘違いだと言っていることが勘違いだといくつ見つけられますか。人間の間違い(human error(125))の種類と対策
https://qiita.com/kaizen_nagoya/items/ae391b77fffb098b8fb4

プログラマの「プログラムが書ける」思い込みは強みだ。３つの理由。仮説（168）統計と確率(17) , OSEK(79)
https://qiita.com/kaizen_nagoya/items/bc5dd86e414de402ec29

出力(output)と呼ばないで。これは状態(state)です。
https://qiita.com/kaizen_nagoya/items/80b8b5913b2748867840

これからの情報伝達手段の在り方について考えてみよう。炎上と便乗。
https://qiita.com/kaizen_nagoya/items/71a09077ac195214f0db

ISO/IEC JTC1 SC7 Software and System Engineering
https://qiita.com/kaizen_nagoya/items/48b43f0f6976a078d907

アクセシビリティの知見を発信しよう！（再び）
https://qiita.com/kaizen_nagoya/items/03457eb9ee74105ee618

統計論及確率論輪講（再び）
https://qiita.com/kaizen_nagoya/items/590874ccfca988e85ea3

読者の心をグッと惹き寄せる7つの魔法
https://qiita.com/kaizen_nagoya/items/b1b5e89bd5c0a211d862

「@kazuo_reve 新人の方によく展開している有益な情報」確認一覧
https://qiita.com/kaizen_nagoya/items/b9380888d1e5a042646b

ソースコードで議論しよう。日本語で議論するの止めましょう（あるプログラミング技術の議論報告）
https://qiita.com/kaizen_nagoya/items/8b9811c80f3338c6c0b0

脳内コンパイラの3つの危険
https://qiita.com/kaizen_nagoya/items/7025cf2d7bd9f276e382

心理学の本を読むよりはコンパイラ書いた方がよくね。仮説（34）
https://qiita.com/kaizen_nagoya/items/fa715732cc148e48880e

NASAを超えるつもりがあれば読んでください。
https://qiita.com/kaizen_nagoya/items/e81669f9cb53109157f6

データサイエンティストの気づき!「勉強して仕事に役立てない人。大嫌い!!」『それ自分かも?』ってなった!!!
https://qiita.com/kaizen_nagoya/items/d85830d58d8dd7f71d07

「ぼくの好きな先生」「人がやらないことをやれ」プログラマになるまで。仮説（37）　
https://qiita.com/kaizen_nagoya/items/53e4bded9fe5f724b3c4

なぜ経済学徒を辞め、計算機屋になったか（経済学部入学前・入学後・卒業後対応） 転職(1)
https://qiita.com/kaizen_nagoya/items/06335a1d24c099733f64

プログラミング言語教育のXYZ。 仮説（52）
https://qiita.com/kaizen_nagoya/items/1950c5810fb5c0b07be4

【24卒向け】9ヶ月後に年収１０００万円を目指す。二つの関門と三つの道。
https://qiita.com/kaizen_nagoya/items/fb5bff147193f726ad25

「【25卒向け】Qiita Career Meetup for STUDENT」予習の勧め
https://qiita.com/kaizen_nagoya/items/00eadb8a6e738cb6336f

大学入試不合格でも筆記試験のない大学に入って卒業できる。卒業しなくても博士になれる。
https://qiita.com/kaizen_nagoya/items/74adec99f396d64b5fd5

全世界の不登校の子供たち「博士論文」を書こう。世界子供博士論文遠隔実践中心 安全(99)
https://qiita.com/kaizen_nagoya/items/912d69032c012bcc84f2

小川メソッド　覚え（書きかけ）
https://qiita.com/kaizen_nagoya/items/3593d72eca551742df68

DoCAP（ドゥーキャップ）って何ですか？
https://qiita.com/kaizen_nagoya/items/47e0e6509ab792c43327

views 20,000越え自己記事一覧
https://qiita.com/kaizen_nagoya/items/58e8bd6450957cdecd81

Views１万越え、もうすぐ１万記事一覧 最近いいねをいただいた213記事
https://qiita.com/kaizen_nagoya/items/d2b805717a92459ce853

amazon 殿堂入りNo1レビュアになるまで。仮説(102)
https://qiita.com/kaizen_nagoya/items/83259d18921ce75a91f4

100以上いいねをいただいた記事16選
https://qiita.com/kaizen_nagoya/items/f8d958d9084ffbd15d2a

小川清最終講義、最終講義（再）計画, Ethernet(100) 英語(100) 安全(100)
https://qiita.com/kaizen_nagoya/items/e2df642e3951e35e6a53

＜この記事は個人の過去の経験に基づく個人の感想です。現在所属する組織、業務とは関係がありません。＞
This article is an individual impression based on my individual experience. It has nothing to do with the organization or business to which I currently belong.

文書履歴(document history)

ver. 0.01 初稿 20190508 朝
ver. 0.02 誤記訂正 20190508 午前
ver. 0.03 手順、参考文献追記　昼
ver. 0.04 遺伝子　追記 20190508 午後
ver. 0.05 ３視点追記 20190509
ver. 0.06 ありがとう追記 20230601

最後までおよみいただきありがとうございました。

いいね　💚、フォローをお願いします。

Thank you very much for reading to the last sentence.

Please press the like icon 💚　and follow me for your happy life.

0
1
0

Register as a new user and use Qiita more conveniently

  1. You get articles that match your needs
  2. You can efficiently read back useful information
  3. You can use dark theme
What you can do with signing up
Sign upLogin
0
1

Delete article

Deleted articles cannot be recovered.

Draft of this article would be also deleted.

Are you sure you want to delete this article?